Anti-angiogenic therapy is a critical strategy, with vascular endothelial growth factor receptor (VEGFR) inhibitors playing a pivotal role in blocking tumor angiogenesis (Zhao et al., 2024). The gene discussed is KDR; the disease is neoplasm.